|1.||Kondapi, Anand K: 3 articles (06/2006 - 02/2004)|
|2.||Lee, Dean: 1 article (10/2010)|
|3.||Aguilera, Dolly: 1 article (10/2010)|
|4.||Gopalakrishnan, Vidya: 1 article (10/2010)|
|5.||Wolff, Johannes E A: 1 article (10/2010)|
|6.||Das, Chandra M: 1 article (10/2010)|
|7.||Taylor, Pete: 1 article (10/2010)|
|8.||Zage, Peter E: 1 article (10/2010)|
|9.||Satyanarayana, Nathamu: 1 article (06/2006)|
|10.||Saikrishna, A D: 1 article (06/2006)|
12/27/1995 - "In contrast to topoisomerase II-alpha, topoisomerase II-beta was expressed in most normal as well as in tumor tissue samples, at a similar level. "
06/30/1995 - "These studies of human topoisomerase II beta in concert with alpha should aid the determination of their individual roles in cancer chemotherapy and should facilitate the design, targeting, and testing of cytotoxic antitumor agents."
08/07/1996 - "Interestingly, a correlation was found between tumor response to chemotherapy and the expression level of the isoform alpha (but not of topoisomerase II beta and topoisomerase I). "
04/15/2002 - "XK469 (NSC697887), (+/-)-2-[4-(7-Chloro-2-quinoxaliny)oxy]-phenoxy propionic acid, an analog of the herbicide Assure(R), which possesses antitumor activity, especially against murine solid tumors and human xenografts, has recently been found to be the first topoisomerase II beta poison. "
12/27/1995 - "In tumor cells, there was a positive association between expression of topoisomerase II-alpha and Ki-67, a marker of cell proliferation, as assessed by immunohistochemistry, but not with topoisomerase II-beta or topoisomerase I. Clinical characteristics of the patients, and their survival did not appear to be correlated to the level of expression of any of the topoisomerase genes, although a trend towards a shorter survival was observed in patients whose tumors expressed relatively high topoisomerase II-alpha mRNA levels. "
|3.||Melanoma (Melanoma, Malignant)
11/01/1994 - "VM-26 also had a protective effect on topoisomerase II beta in HL-60 leukemia and WiDR colon carcinoma cells. "
10/15/1991 - "Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform."
04/15/1995 - "Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line."
06/15/2006 - "The Topoisomerase II beta over-expressing neuroblastoma cell line shows a higher sensitivity to these compounds compared to the Sup-T1 cell line. "
10/01/2010 - "These results suggest a potential epigenetic mechanism of regulation of the topoisomerase II-beta gene and a possible role for its increased expression in the sensitivity of SK-N-AS neuroblastoma cells to etoposide."
10/01/2010 - "Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines."
|1.||Antineoplastic Agents (Antineoplastics)
|2.||DNA topoisomerase II alpha
|3.||Messenger RNA (mRNA)
|4.||Type I DNA Topoisomerases (Topoisomerase I)
|6.||Etoposide (VP 16)
|7.||Type II DNA Topoisomerases (Topoisomerase II)
|8.||Glutathione S-Transferase pi
|9.||Multidrug Resistance-Associated Proteins
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)